secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-09-18T21:16:51+00:00
Accession:  0001104659-26-108980
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve Zymeworks merger; closing expected Sept 23, 2026
---------------------------------------------------------------------

- Merger Proposal approved: 40,993,370 for, 8,671 against, 84,733 abstentions (>2/3 required).
- Advisory merger-related compensation proposal also approved (40,587,829 for, 470,381 against).
- Merger expected to close on or about Sept 23, 2026; Theravance to become wholly owned subsidiary of Zymeworks.
- CVR Agreement contingent consideration remains subject to future payment conditions.
- Quorum of 79.14% (41,086,774 shares) present; adjournment proposal not needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/0001104659-26-108980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926108980/tm2625672d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-108980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer